MedTrace Logo

Good EULAR Response In Patients With Early Rheumatoid Arthritis

NCT01558089 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2016-11-11

Study results available
· View outcomes & findings →

Summary

This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece

Conditions

Interventions

DRUG

etanercept

according to SmPC and clinical practice

DRUG

methotrexate

according to SmPC and clinical practice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01558089 on ClinicalTrials.gov